The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation ...

LA JOLLA, Calif. — You could easily mistake it for a big CD rack. Inside the lab at the California Institute of Biomedical Research, known as Calibr, sits a stacked array of several dozen plastic ...

LA JOLLA, Calif., Feb. 6, 2024 /PRNewswire/-- The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that AbbVie (NYSE: ABBV ...

In March 2012, the California Institute for Biomedical Research (Calibr), a nonprofit devoted to translating basic science into drug candidates, launched amid much fanfare. Fueling the hype was an ...

LA JOLLA, Calif., May 23, 2014 /PRNewswire-USNewswire/ -- The California Institute for Biomedical Research (Calibr) has received a Translation Award from the Wellcome Trust to develop a novel ...

LA JOLLA, CA— Calibr, a division of Scripps Research focused on the “bench to bedside” development of transformative medicines, today announced encouraging preliminary data from the first nine ...

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the ...

Peter G. Schultz, the noted chemist and biotech entrepreneur, sure doesn’t think small. His new biomedical research institute in La Jolla, called Calibr, is researching CAR T cell therapy for cancer, ...

After scrapping plans to grab a quick FDA nod for Rova-T, AbbVie is licensing CAR-T technology from Calibr to create safer, “switchable” CAR-T treatments for solid tumors. AbbVie will pay an ...

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the ...

CAR-T cell therapies rely on gathering a patient's own T cells, modifying them to specifically target cancer cells, and delivering them back to the patient where they eradicate cancer cells in the ...